IMMUNOGLOBULIN A NEPHROPATHY
Clinical trials for IMMUNOGLOBULIN A NEPHROPATHY explained in plain language.
Never miss a new study
Get alerted when new IMMUNOGLOBULIN A NEPHROPATHY trials appear
Sign up with your email to follow new studies for IMMUNOGLOBULIN A NEPHROPATHY, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise in slowing kidney disease
Disease control OngoingThis study tests an investigational drug called povetacicept in adults with IgA nephropathy, a kidney disease that can lead to kidney failure. About 605 participants will receive either the drug or a placebo to see if it reduces protein in the urine and preserves kidney function …
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY
Phase: PHASE3 • Sponsor: Alpine Immune Sciences Inc, A Subsidiary of Vertex • Aim: Disease control
Last updated May 17, 2026 07:37 UTC
-
New hope for kidney disease: drug shows promise in slowing IgA nephropathy
Disease control OngoingThis study tests a new drug called sparsentan against a standard blood pressure medication in 406 adults with IgA nephropathy, a kidney disease. The goal is to see if sparsentan can better protect the kidneys over about 2 years by reducing protein in the urine and slowing kidney …
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY
Phase: PHASE3 • Sponsor: Travere Therapeutics, Inc. • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New drug shows promise for Hard-to-Treat kidney diseases
Disease control OngoingThis study tests a new drug called povetacicept in people with certain autoimmune kidney diseases, including lupus nephritis and IgA nephropathy. The goal is to see if it is safe and can help control the disease. Participants receive the drug every 4 weeks for at least 6 months, …
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY
Phase: PHASE1, PHASE2 • Sponsor: Alpine Immune Sciences, Inc. • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New drug shows promise in slowing kidney disease for IgA patients
Disease control ENROLLING_BY_INVITATIONThis study tests the long-term safety and effectiveness of sibeprenlimab, an experimental drug, in about 600 adults with IgA nephropathy—a kidney disease that can lead to kidney failure. Participants must have completed a prior sibeprenlimab study and may benefit from continued t…
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY
Phase: PHASE2, PHASE3 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New drug shows promise in slowing kidney disease for IgA nephropathy patients
Disease control OngoingThis study tests a drug called sibeprenlimab in 530 adults with IgA nephropathy, a kidney disease that can lead to kidney failure. The goal is to see if the drug can reduce protein in the urine and slow the loss of kidney function over time. Participants receive either the drug o…
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY
Phase: PHASE3 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
New hope for kidney patients: experimental drug targets IgA nephropathy in major trial
Disease control OngoingThis phase 3 study tests whether BION-1301 can protect kidney function in adults with IgA nephropathy, a disease where antibodies build up in the kidneys. About 383 participants will receive either the drug or a placebo. The main goal is to see if the drug slows the decline in ki…
Matched conditions: IMMUNOGLOBULIN A NEPHROPATHY
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 13, 2026 15:59 UTC